Summary Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage. Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da. Market Segment as follows: By Region Asia-Pacific North America Europe South America Middle East & Africa By Type Enoxaparin Dalteparin Tinzaparin Fraxiparine By Application Treatment of Venous Thromboembolism Complications of Pregnancy Cardioversion of Atrial Fibrillation/Flutter Others By Company Aspen Sanofi-aventis Pfizer Opocrin CSBIO Dongying Tiandong Pharmaceutical Changzhou Qianhong Bio-pharma Techdow Yantai Dongcheng Pharmaceutical Group The main contents of the report including: Section 1: Product definition, type and application, global and regional market overview; Section 2: Global and regional Market competition by company; Section 3: Global and regional sales revenue, volume and price by type; Section 4: Global and regional sales revenue, volume and price by application; Section 5: Regional export and import; Section 6: Company information, business overview, sales data and product specifications; Section 7: Industry chain and raw materials; Section 8: SWOT and Porter's Five Forces; Section 9: Conclusion.
Table of Contents 1 Market Overview 1.1 Market Segment Overview 1.1.1 Product Definition 1.1.2 Market by Type 1.1.2.1 Enoxaparin 1.1.2.2 Dalteparin 1.1.2.3 Tinzaparin 1.1.2.4 Fraxiparine 1.1.3 Market by Application 1.1.3.1 Treatment of Venous Thromboembolism 1.1.3.2 Complications of Pregnancy
